CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aslan Pharmaceuticals Limited  (ASLN)
Other Ticker:  
 

Aslan Pharmaceuticals Limited's Total Debt to Equity

ASLN's quarterly Total Debt to Equity and Total Debt, Equity growth


Due to debt repayement of 0% Aslan Pharmaceuticals Limited improved Total Debt to Equity in forth quarter 2022 to 3.55, a new company high.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 187 other companies have achieved lower Total Debt to Equity than Aslan Pharmaceuticals Limited in the IV Quarter 2022. While Total Debt to Equity total ranking has deteriorated compared to the third quarter 2022 from 3199 to 3282 .

Explain Debt to Equity Ratio?
What is the structure of ASLN´s Total Debt?
How valuable is the ASLN´s Equity?


ASLN Total Debt to Equity (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity Change -85.4 % -85.4 % -85.4 % -85.4 % -
Y / Y Total Debt Change -3.89 % -3.89 % -3.89 % -3.89 % 69.58 %
Total Debt to Equity MRQ 3.55 3.55 3.55 3.55 0.54
ASLN's Total Ranking # 3282 # 3199 # 3199 # 3199 # 1974
Seq. Equity Change 0 % 0 % 0 % -85.4 % 0 %
Seq. Total Debt Change 0 % 0 % 0 % -3.89 % 0 %

New: More ASLN's historic Total Debt to Equity Ratios >>


Total Debt to Equity forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 188
Healthcare Sector # 462
Overall Market # 3282


Total Debt to Equity Statistics
High Average Low
3.55 1.52 0.47
(Dec 31 2022)   (Dec 31 2018)




Financial Statements
Aslan Pharmaceuticals Limited's Equity $ 8 Millions Visit ASLN's Balance sheet
Aslan Pharmaceuticals Limited's Total Debt $ 30 Millions Visit ASLN's Balance sheet
Source of ASLN's Sales Visit ASLN's Sales by Geography


Cumulative Aslan Pharmaceuticals Limited's Total Debt to Equity

ASLN's Total Debt to Equity for the trailling 12 Months

ASLN Total Debt to Equity

 (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity TTM Growth -85.4 % -85.4 % -85.4 % -85.4 % -
Y / Y Total Debt TTM Growth -3.89 % -3.89 % -3.89 % -3.89 % 69.58 %
Total Debt to Equity TTM 3.55 1.45 0.92 0.68 0.54
Total Ranking TTM # 3417 # 124 # 0 # 0 # 121
Seq. Equity TTM Growth 0 % 0 % 0 % -85.4 % 0 %
Seq. Total Debt TTM Growth 0 % 0 % 0 % -3.89 % 0 %

Debt to equity ratio ranking by company, industry and sector >> Back to ASLN Financial Strength Comparisons >> Go to Compare ASLN Total Debt to Equity Ratio to its Competitors

On the trailing twelve months basis Despite of the debt repayement of 0% in the trailing twelve months ending in IV Quarter 2022, Total Debt to Equity improved to 3.55, a new company high.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 223, during the past 12 months, other companies have achieved lower Total Debt to Equity than Aslan Pharmaceuticals Limited. While Total Debt to Equity total ranking has deteriorated during the twelve months ending in the IV Quarter 2022, compared to the prior period, from 124 to 3417.

Explain Debt to Equity Ratio?
What is the structure of ASLN´s Total Debt?
How valuable is the ASLN´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 224
Healthcare Sector # 527
Within the Market # 3417


trailing twelve months Total Debt to Equity Statistics
High Average Low
3.55 1.38 0.47
(Dec 31 2022)   (Dec 31 2018)




Companies with similar Total Debt to Equity in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Total Debt to EquityDec 31 2022 MRQ Total DebtDec 31 2022 MRQ Equity
Travere Therapeutics Inc   8.76 $ 375.545  Millions$ 42.851  Millions
9 Meters Biopharma Inc   8.17 $ 19.616  Millions$ 2.401  Millions
Clene Inc   4.91 $ 15.901  Millions$ 3.237  Millions
Seres Therapeutics Inc   4.73 $ 51.047  Millions$ 10.783  Millions
Puma Biotechnology Inc   4.55 $ 98.307  Millions$ 21.608  Millions
Xeris Biopharma Holdings Inc   4.14 $ 187.075  Millions$ 45.187  Millions
Sarepta Therapeutics Inc   4.01 $ 1,544.292  Millions$ 384.950  Millions
Evolus Inc   3.89 $ 71.879  Millions$ 18.499  Millions
Harrow Inc   3.82 $ 104.174  Millions$ 27.240  Millions
Omeros Corp  3.68 $ 315.287  Millions$ 85.684  Millions
Abbvie inc   3.66 $ 63,271.000  Millions$ 17,287.000  Millions
Collegium Pharmaceutical Inc   3.60 $ 700.951  Millions$ 194.842  Millions
Intercept Pharmaceuticals inc   3.57 $ 332.673  Millions$ 93.077  Millions
Aslan Pharmaceuticals Limited  3.55 $ 29.656  Millions$ 8.365  Millions
Amicus Therapeutics inc   3.19 $ 391.990  Millions$ 123.047  Millions
Janone Inc   2.55 $ 5.892  Millions$ 2.307  Millions
Teva Pharmaceutical Industries Limited  2.44 $ 21,212.000  Millions$ 8,691.000  Millions
Kala Bio inc   2.26 $ 42.937  Millions$ 18.974  Millions
Gossamer Bio Inc   1.95 $ 23.601  Millions$ 12.077  Millions
Fortress Biotech Inc   1.89 $ 94.678  Millions$ 50.025  Millions
Jazz Pharmaceuticals Plc  1.86 $ 5,724.341  Millions$ 3,085.734  Millions
Morphosys Ag  1.85 $ 326.645  Millions$ 176.299  Millions
Ascendis Pharma A  1.83 $ 540.911  Millions$ 294.950  Millions
Zoetis Inc   1.80 $ 7,904.000  Millions$ 4,403.000  Millions
Phibro Animal Health Corporation  1.77 $ 476.226  Millions$ 268.370  Millions
Paxmedica Inc   1.60 $ 0.174  Millions$ 0.109  Millions
Nabriva Therapeutics Plc  1.59 $ 5.221  Millions$ 3.293  Millions
Ocular Therapeutix Inc   1.53 $ 54.006  Millions$ 35.379  Millions
Eli Lilly And Company  1.51 $ 16,238.600  Millions$ 10,775.400  Millions
Journey Medical Corporation  1.34 $ 22.774  Millions$ 16.982  Millions

Date modified: 2023-03-26T05:28:45+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com